Market Overview:
The global chidamide market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and growing awareness about chidamide. The global chidamide market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into 5 mg and others. The 5 mg segment is expected to account for a major share of the global chidamide market during the forecast period owing to its high efficacy and better patient compliance as compared to other types of chidamide formulations. On the basis of application,the market is divided into PECL treatment and other cancers treatment.
Product Definition:
Chidamide is used to treat relapsed or refractory Hodgkin lymphoma. It is important because it can help people with Hodgkin lymphoma who have not responded to other treatments.
5 mg:
Chidamide is used for the treatment of eczema and atopic dermatitis. It's a topical anti-inflammatory drug that works by decreasing itching and inflammation. The medicine has also been found to be effective in treating mild to moderate plaque psoriasis when used as directed by doctors.
The medicine was approved by the U.
Others:
Others is a group of drugs that are used to treat diseases related to the immune system. The Others segment includes drugs such as rituximab, mongersen, and zanamivir. Chidamide is an antiviral drug used in the treatment of colds and flu's. It works by blocking viral enzymes involved in transcription & replication of virus particles inside cells.
Application Insights:
The other cancers treatment segment dominated the global chidamide market in 2017. This can be attributed to increasing prevalence of cancer across the globe. For instance, as per the World Health Organization (WHO), an estimated 1.7 million new cases of cancer were reported in 2016, which include breast cancer, lung and bronchus carcinoma, colorectal cancer and prostate carcinoma among others. The same year, around 585 thousand people died due to these diseases globally.
PECL treatment accounted for a significant share in the overall revenue generation for chidamide in 2017 owing to its high efficacy against this disease coupled with low toxicity towards cells compared to other chemotherapeutic drugs used for its treatment such as doxorubicin or cisplatin among others that are used worldwide by various pharmaceutical companies including Pfizer Inc., Novartis AG., GlaxoSmithKline Plc., etc.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Celgene Corporation; and Merck & Co., Inc. Moreover, these companies are constantly engaged in strategic initiatives such as new product launches, partnerships, mergers and acquisitions to enhance their geographical reach and customer base. For instance, in May 2018, Pfizer acquired Medarex LLC’s cancer care business including brands Mylan N.V., generic drugs Humira (adalimumab) and Enbrel (etanercept), Cinryze (cetuximab), Zolgensma (zingalemtuzumab), Mavenir (mizolastat) for commercialization through its subsidiary company Pfizer Canada Ltd.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for Chidamide market. According to the World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths from the disease. This number is expected to increase to 21 million new cases and 13 million deaths by 2030. This will create a huge demand for Chidamide and other anticancer drugs, which will drive the growth of Chidamide market.
- Rising awareness about cancer treatment options: The rising awareness about various types of cancers and their treatment options is another major growth driver for Chidamide market. People are becoming more aware about the benefits of using targeted therapies such as Chidamide for treating different types of cancers, which is driving the demand for this drug worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Chidamide Market Research Report
By Type
5 mg, Others
By Application
PECL Treatment, Other Cancers Treatment
By Companies
Shenzhen Chipscreen, HuyaBio, GNT Biotech Medicals Corporation, Japan Eisai
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
187
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global Chidamide Market Report Segments:
The global Chidamide market is segmented on the basis of:
Types
5 mg, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
PECL Treatment, Other Cancers Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Shenzhen Chipscreen
- HuyaBio
- GNT Biotech Medicals Corporation
- Japan Eisai
Highlights of The Chidamide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5 mg
- Others
- By Application:
- PECL Treatment
- Other Cancers Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chidamide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chidamide is an anti-psychotic medication. It works by blocking the action of certain chemicals in the brain that can cause symptoms like hallucinations and delusions.
Some of the major players in the chidamide market are Shenzhen Chipscreen, HuyaBio, GNT Biotech Medicals Corporation, Japan Eisai.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chidamide Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chidamide Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chidamide Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chidamide Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chidamide Market Size & Forecast, 2018-2028
4.5.1 Chidamide Market Size and Y-o-Y Growth
4.5.2 Chidamide Market Absolute $ Opportunity
Chapter 5 Global Chidamide Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chidamide Market Size Forecast by Type
5.2.1 5 mg
5.2.2 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chidamide Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chidamide Market Size Forecast by Applications
6.2.1 PECL Treatment
6.2.2 Other Cancers Treatment
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chidamide Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chidamide Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chidamide Analysis and Forecast
9.1 Introduction
9.2 North America Chidamide Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chidamide Market Size Forecast by Type
9.6.1 5 mg
9.6.2 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chidamide Market Size Forecast by Applications
9.10.1 PECL Treatment
9.10.2 Other Cancers Treatment
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chidamide Analysis and Forecast
10.1 Introduction
10.2 Europe Chidamide Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chidamide Market Size Forecast by Type
10.6.1 5 mg
10.6.2 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chidamide Market Size Forecast by Applications
10.10.1 PECL Treatment
10.10.2 Other Cancers Treatment
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chidamide Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chidamide Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chidamide Market Size Forecast by Type
11.6.1 5 mg
11.6.2 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chidamide Market Size Forecast by Applications
11.10.1 PECL Treatment
11.10.2 Other Cancers Treatment
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chidamide Analysis and Forecast
12.1 Introduction
12.2 Latin America Chidamide Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chidamide Market Size Forecast by Type
12.6.1 5 mg
12.6.2 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chidamide Market Size Forecast by Applications
12.10.1 PECL Treatment
12.10.2 Other Cancers Treatment
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chidamide Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chidamide Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chidamide Market Size Forecast by Type
13.6.1 5 mg
13.6.2 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chidamide Market Size Forecast by Applications
13.10.1 PECL Treatment
13.10.2 Other Cancers Treatment
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chidamide Market: Competitive Dashboard
14.2 Global Chidamide Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Shenzhen Chipscreen
14.3.2 HuyaBio
14.3.3 GNT Biotech Medicals Corporation
14.3.4 Japan Eisai
